Hepatitis G virus IgG (HGV-IgG) ELISA Kit

Short Description:

Hepatitis G virus (HGV), also known as GB virus C (GBV-C) or human pegivirus type 1 (HPgV-1), is a single-stranded, positive-sense RNA virus belonging to the Pegivirus genus in the Flaviviridae family. It shares structural similarities with hepatitis C virus (HCV) but is lymphotropic rather than hepatotropic, replicating primarily in lymphocytes and bone marrow rather than hepatocytes. HGV is transmitted primarily through parenteral routes, including exposure to infected blood or blood products, intravenous drug use, and hemodialysis, with additional risks via sexual contact and vertical (mother-to-child) transmission.

HGV infection is common worldwide, with viremia prevalence ranging from 1-5% in healthy blood donors in developed countries to higher rates in developing regions and high-risk groups (e.g., up to 20-40% in individuals with HIV or HCV). It frequently coexists with other blood-borne viruses such as HBV, HCV, or HIV due to shared transmission pathways. Extensive clinical studies have failed to establish HGV as a causative agent of acute or chronic hepatitis, fulminant liver failure, or other liver diseases; most infections are asymptomatic, with normal liver enzymes and no histologic evidence of hepatitis. Coinfection with HBV or HCV does not appear to exacerbate liver disease severity or progression.

Following HGV infection, the majority of immunocompetent individuals clear viremia spontaneously within years, often accompanied by the development of antibodies to the envelope glycoprotein E2 (anti-E2, detected as anti-HGV IgG). Anti-HGV IgG antibodies typically emerge after viral clearance and persist long-term, serving as a reliable serological marker of past (resolved) infection and potential immunity against reinfection. In contrast, ongoing viremia (detected by RNA testing) indicates active infection, during which broad antibody responses are limited. Detection of anti-HGV IgG is valuable for epidemiological studies, assessing prior exposure in high-risk populations, and distinguishing resolved from persistent infection, particularly in contexts of coinfection with other viruses.

Send email to us

Product Detail

Product Tags

Principle:

This kit employs the indirect enzyme-linked immunosorbent assay (ELISA) principle to detect hepatitis G virus IgG antibodies (anti-HGV IgG, primarily directed against the envelope glycoprotein E2) in human serum or plasma samples. The polystyrene microwell strips are pre-coated with recombinant hepatitis G virus (HGV) antigens. Upon addition of the serum or plasma specimen, any anti-HGV IgG antibodies present in the sample bind specifically to the immobilized antigens, while unbound components are removed by washing. In the subsequent step, horseradish peroxidase (HRP)-conjugated mouse anti-human IgG antibodies are added, which bind to the captured human IgG. Following another wash to remove unbound HRP conjugates, a chromogenic substrate (TMB) is added to the wells. In the presence of the antigen - anti-HGV IgG - HRP-anti-human IgG immunocomplex, the HRP enzyme catalyzes the substrate reaction, producing a blue color that is proportional to the concentration of anti-HGV IgG. The reaction is halted by adding a stop solution (typically 50 μL per well), which shifts the color to yellow. The absorbance (optical density) is then measured using a microplate reader at the appropriate wavelength (e.g., 450 nm, with a reference wavelength of 620-690 nm if required) to determine the presence and level of anti-HGV IgG antibodies in the sample.

Product Features:

High sensitivity, specificity and stability

Product Specification:

Principle	Enzyme linked immunosorbent assay
Type	Indirect Method
Certificate	NMPA
Specimen	Human serum / plasma
Specification	48T / 96T
Storage temperature	2-8℃
Shelf life	12 months